Sign In
Buy CNSP
$5.24
+0.320 (+6.50%)
At Close: Jun 03, 2026
CNSP Stock Price Increases Over 15%: Why It Happened
10:20am, Tuesday, 29'th Jun 2021
The stock price of CNS Pharmaceuticals Inc (NASDAQ: CNSP) increased by over 15% during intraday trading this morning. This is why it happened.
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
08:35am, Tuesday, 29'th Jun 2021
HOUSTON, June 29, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a
CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index
09:05am, Thursday, 17'th Jun 2021
HOUSTON, June 17, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary an
CNS Pharmaceuticals Begins Enrollment, Screening Brain Cancer Study With Berubicin
12:59pm, Wednesday, 19'th May 2021
CNS Pharmaceuticals Inc (NASDAQ: CNSP) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma Multiforme (GBM). The company intends to en
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
08:05am, Wednesday, 19'th May 2021
HOUSTON, May 19, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary
CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Outlook
09:05am, Friday, 14'th May 2021
HOUSTON, May 14, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary
CNS Pharmaceuticals to Present at the Q2 Virtual Investor Summit
08:35am, Tuesday, 11'th May 2021
HOUSTON, May 11, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a
CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference
09:00am, Monday, 15'th Mar 2021
HOUSTON, March 15, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for prima
Polish Regulatory Authority Issues Positive Opinion For CNS Pharma's Brain Cancer Candidate
01:45pm, Thursday, 18'th Feb 2021
CNS Pharmaceuticals Inc's (NASDAQ: CNSP) partner WPD Pharmaceuticals received a favorable opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland, for its planned upcomin
7 Penny Stocks on a Tear Right Now and Still Worth Buying
07:31am, Tuesday, 29'th Dec 2020
Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
08:00am, Monday, 28'th Dec 2020
HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc . (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary a
CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin
04:05pm, Thursday, 17'th Dec 2020
HOUSTON, Dec. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary an
CNS Pharmaceuticals to Provide Second Quarter 2020 Business Update on Thursday, August 13, 2020
12:00pm, Tuesday, 11'th Aug 2020
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that CEO, John M. Clima
CNS Pharmaceuticals Recognizes Glioblastoma Awareness Day
12:00pm, Wednesday, 22'nd Jul 2020
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and c
Transdermal Drug Delivery Market Analysis 2020-2027 and the Expected Impact of COVID-19 - ResearchAndMarkets.com
12:00am, Wednesday, 22'nd Jul 2020
The
